Repository logo

Browsing by Issue Date, starting with "2025-03-19"

Filter results by year or month
Now showing 1 - 1 of 1
  • Adverse effects of the drugs methylphenidate, atomoxetine and lisdexamfetamine reported to the European Pharmacovigilance System
    Publication . Motete, Mpho; Capela, João Paulo Soares; Silva, Ana Marta
    Attention deficit hyperactivity disorder (ADHD) is a common condition affecting both children and adults. In Portugal, three primary medications—methylphenidate, atomoxetine, and lisdexamfetamine—are approved for ADHD treatment, with methylphenidate being the most widely prescribed since 2003. This study aims to investigate the adverse effects of these medications as reported in the European Pharmacovigilance System (EPS) over the past decade. The study begins by reviewing the pharmacology, clinical applications, and efficacy of each drug based on clinical trials, providing context for their widespread use. It then analyses EPS data on adverse drug reactions (ADRs) was recorded from 2013 to 2024, focusing on age, gender, and geographical differences among the affected populations. Results indicate that ADRs vary significantly across demographics, with methylphenidate showing the highest number of reported cases, particularly among younger patients, while lisdexamfetamine and atomoxetine demonstrate distinct adverse profiles. Males report higher ADRs with methylphenidate and atomoxetine, while females exhibit more ADRs with lisdexamfetamine, suggesting potential gender-related differences. Additionally, nervous system and psychiatric disorders are the most reported ADRs across all three drugs, with cardiovascular issues appearing more frequently in adults and older populations. This study’s findings underscore the importance of demographic-specific monitoring, revealing patterns that can inform safer prescribing practices and support personalized treatment strategies for ADHD. By expanding on pharmacovigilance data across diverse populations, the study aims to enhance understanding of these medications' safety profiles and contribute to improved management and outcomes for individuals with ADHD.
    2025-03-19Master thesis Restricted access Show more